This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor
(TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for
F508del and a minimal function mutation (F/MF subjects).

Researchers want to learn more about telehealth pulmonary rehabilitation programs that help
people with Chronic obstructive pulmonary disease (COPD) improve physical activity and
quality of life.

This is an open-label study to evaluate the safety of continued therapy with oral
treprostinil in subjects who have completed Study TDE-HF-301. This study will provide
long-term, open-label data regarding the effect of continued long-term oral treprostinil
therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with
preserved ejection fraction (HFpEF). Subject visits will occur at Baseline, Weeks 6, 12, 18,
24, and every 12 weeks thereafter until either oral treprostinil becomes commercially
available to treat PH associated with HFpEF or the study is discontinued by the Sponsor.

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind,
placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary
hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF).
Once randomized, subjects will take the initial dose of study drug at the study site on the
day of randomization. Subjects will return to the study site for visits scheduled at Weeks 6,
12, 18, and 24. The treatment phase of the study will last approximately 24 weeks.

Study VX16-661-114 (Study 114) is a Phase 3b, randomized, double-blind, placebo-controlled,
parallel group, multicenter study in subjects aged 12 years and older with CF who are
homozygous for the F508del mutation on the CFTR gene and who discontinued treatment with
Orkambi due to respiratory symptoms considered related to treatment. This study is designed
to evaluate the safety and efficacy of TEZ/IVA.

This trial will consist of three arms: Part A, Part B, and Part C. Part A has two groups.
The first group will enroll adult subjects with cystic fibrosis (CF) into a single ascending
dose (SAD) treatment group. The second group will enroll adult subjects with CF, including
those on background treatment with ORKAMBI® and those not on a cystic fibrosis transmembrane
conductance regulator (CFTR) modulator, into a multiple ascending dose (MAD) treatment
group. Part B will enroll adult subjects with CF currently on stable ORKAMBI® background
therapy for a minimum of 3 months into a Phase II treatment group consisting of two cohorts.
Part C will enroll adult subjects with CF, including those on background treatment with
KALYDECO® and those not on a CFTR modulator, into a Phase II treatment group consisting of
three cohorts. Approximately 136 subjects will be enrolled.

The purpose of this study is to examine whether or not providing Chantix (varenicline) will
help African American smokers quit smoking.

The purpose of this study is to test the effectiveness of a culturally-tailored
Internet-based program that helps American Indian (AI) tribal college students quit smoking.